After years of rigorous research and foundational progress, the inflammasome drug development field is reaching a critical inflection point. With long-awaited clinical data now beginning to emerge, momentum is building, and the landscape is evolving rapidly. NodThera has shared encouraging results in Parkinson’s disease and obesity, Ventus has initiated a Phase IIa clinical trial, and Ventyx is progressing a diversified pipeline of inflammasome-targeting assets. As the race for first-in-class success accelerates, the field stands on the cusp of transformative breakthroughs.

Now in its 7th year, the Inflammasome Therapeutics Summit remains the only industry event dedicated exclusively to inflammasome-targeted drug development. Bringing together over 70 leading drug developers, translational scientists, and clinical experts, this summit offers a unique platform to exchange insights, benchmark clinical progress, and shape the next chapter of therapeutic innovation.

Across neuroinflammation, metabolic disorders, and autoimmune diseases, this meeting will explore the most current clinical data, emerging strategies, and scientific advances. Join your peers to hear directly from those driving programs forward, tackle the most pressing translational challenges, and help chart the future of inflammasome therapeutics.